Silvina Levis1,2, Orlando Gómez-Marín2,3,4,5. 1. Geriatric Research, Education and Clinical Center, Miami Veterans Affairs Healthcare System, Miami, Florida. 2. Department of Medicine, Miller School of Medicine, University of Miami, Miami, Florida. 3. Department of Public Health Sciences, Miller School of Medicine, University of Miami, Miami, Florida. 4. Department of Pediatrics, Miller School of Medicine, University of Miami, Miami, Florida. 5. Research Service, Miami Veterans Affairs Healthcare System, Miami, Florida.
Abstract
OBJECTIVES: To determine the effectiveness of vitamin D supplementation in preventing decline in physical function in older men. DESIGN: Randomized, double-blind, placebo-controlled clinical trial. SETTING:Single-center study conducted at a Veterans Affairs Healthcare System. PARTICIPANTS: Sedentary men aged 65 to 90 (mean 72.4 ± 6.8) with baseline 25-hydroxyvitamin D (25(OH)D levels of less than 30 ng/mL and Short Physical Performance Battery (SPPB) test scores of 9 or less (N = 130). INTERVENTION: Daily capsule containingcholecalciferol 4,000 IU daily or placebo for 9 months. MEASUREMENTS: Main outcomes were SPPB score and gait speed. RESULTS: After the intervention, serum 25(OH)D increased from 23.1 ± 5.0 ng/mL to 46.2 ± 12.7 ng/mL in the cholecalciferol group and from 22.5 ± 5.3 ng/mL to 24.0 ± 7.2 ng/mL in the placebo group. At study end, improvements in SPPB score and gait speed were not significantly greater in men receiving cholecalciferol than in those receiving placebo. No differences were found in adverse events or numbers of falls. CONCLUSION:Daily cholecalciferol 4,000 IU for 9 months resulted in significant increases in 25(OH)D concentrations, but achieving these higher levels did not result in improvements in SPPB score or gait speed. These data do not support prescribing vitamin D supplements to older sedentary men to prevent physical function decline.
RCT Entities:
OBJECTIVES: To determine the effectiveness of vitamin D supplementation in preventing decline in physical function in older men. DESIGN: Randomized, double-blind, placebo-controlled clinical trial. SETTING: Single-center study conducted at a Veterans Affairs Healthcare System. PARTICIPANTS: Sedentary men aged 65 to 90 (mean 72.4 ± 6.8) with baseline 25-hydroxyvitamin D (25(OH)D levels of less than 30 ng/mL and Short Physical Performance Battery (SPPB) test scores of 9 or less (N = 130). INTERVENTION: Daily capsule containing cholecalciferol 4,000 IU daily or placebo for 9 months. MEASUREMENTS: Main outcomes were SPPB score and gait speed. RESULTS: After the intervention, serum 25(OH)D increased from 23.1 ± 5.0 ng/mL to 46.2 ± 12.7 ng/mL in the cholecalciferol group and from 22.5 ± 5.3 ng/mL to 24.0 ± 7.2 ng/mL in the placebo group. At study end, improvements in SPPB score and gait speed were not significantly greater in men receiving cholecalciferol than in those receiving placebo. No differences were found in adverse events or numbers of falls. CONCLUSION: Daily cholecalciferol 4,000 IU for 9 months resulted in significant increases in 25(OH)D concentrations, but achieving these higher levels did not result in improvements in SPPB score or gait speed. These data do not support prescribing vitamin D supplements to older sedentary men to prevent physical function decline.
Authors: Elisa J de Koning; Paul Lips; Brenda W J H Penninx; Petra J M Elders; Annemieke C Heijboer; Martin den Heijer; Pierre M Bet; Harm W J van Marwijk; Natasja M van Schoor Journal: Am J Clin Nutr Date: 2019-11-01 Impact factor: 7.045